阿立哌唑治疗精神分裂症临床效果研究

摘要

Objective To explore the clinical effect of aripiprazole in treatment of schizophrenia.Methods Totally 100 patients with schizophrenia from July 2013 to June 2014 were enrolled and randomly divided into aripiprazole group (50 cases) taking aripiprazole orally (the maximum dosage 30 mg/d) for 8 weeks,and olanzapine group (50 cases) taking olanzapine orally (the maximum dosage 20 mg/d) for 8 weeks.The postive and negative syndrome scale (PANSS) score was assessed before and 2,4,6,8 weeks after treatment;the effective rate was calculated and compared between the two groups.The treatment.emergent symptom scale (TESS) was assessed to evaluate the adverse reactions.Results No significant differences of PANSS score before treatment were shown between the two groups.The PANSS scores 2,4,6 and 8 weeks after treatment were significantly reduced compared with those before treatment in both aripiprazole groups [total PANSS score:(75 ± 13) scores,(60 ± 13) scores,(50 ± 10) scores,(46 ± 12) scores vs (90 ± 15) scores] and olanzapine group [(78 ± 14) scores,(63 ±12) scores,(52 ± 12) scores,(49 ± 12) scores vs (90 ± 15) scores] (all P ＜0.05).The effective rate in aripiprazole group was statistically higher than that in olanzapine group [94.0(47/50) vs 90.0％ (45/50),P ＜ 0.05].No serious adverse reactions occurred in both groups;the incidence of adverse reaction in aripiprazole group was significantly lower than that in olanzapine group [46.0％ (23/50) vs 70.0％ (35/50),P ＜0.05].Conclusion The clinical effect of aripiprazole is better than olanzapine regarding treatment of schizophrenia.%目的 探讨阿立哌唑治疗精神分裂症的临床疗效和不良反应.方法 纳入2013年7月至2014年6月就诊于解放军第四二二医院的精神分裂症患者100例,完全随机分为阿立哌唑组和奥氮平组,各50例.阿立哌唑组口服阿立哌唑片,最大剂量30 mg/d;奥氮平组口服奥氮平片,最大剂量20 mg,/d,疗程均为8周.于治疗前,治疗后2、4、6、8周评估阳性与阴性症状量表(PANSS)评分,判定临床疗效;采用治疗出现症状量表(TESS)评估不良反应发生情况.结果 治疗前2组PANSS评分总分差异无统计学意义(P＞0.05),治疗后2、4、6和8周后阿立哌唑组和奥氮平组PANSS评分总分均较治疗前均明显下降[阿立哌唑组:(75±13)、(60±13)、(50±10)、(46±12)分比(90±15)分;奥氮平组:(78±l4)、(63±12)、(52±12)、(49±12)分比(90±15)分;均P＜0.05].阿立哌唑组总有效率高于奥氮平组[94.0％(47/50)比90.0％(45/50),P＜0.05).阿立哌唑组和奥氮平组均未发生严重不良反应,阿立哌唑组不良反应发生率低于奥氮平组[46.0％(23/50)比70.0％(35/50),P＜0.05].结论 阿立哌唑治疗精神分裂症疗效优于奥氮平,安全性较好.